期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 11, 期 3, 页码 307-318出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2015.1009897
关键词
biologic agents; certolizumab pegol; psoriatic arthritis; tumor necrosis factor alpha inhibitors
类别
Certolizumab pegol (CZP) is a TNF-alpha inhibitor approved for the treatment of psoriatic arthritis in 38 countries, including many European countries and the USA. It is a pegylated humanized anti-TNF-alpha antigen-binding fragment, administered subcutaneously. As other TNF-alpha antibodies, CZP binds to and neutralizes both soluble and membrane TNF-alpha. In contrast to whole antibodies and etanercept, CZP does not activate antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity, as it does not have an Fc piece. CZP showed efficacy in improving skin scores and patient reported outcomes in a Phase II study of 176 adults with moderate-to-severe plaque psoriasis. In a Phase III study of CZP in 409 psoriatic arthritis patients, CZP treatment resulted in improvements in peripheral arthritis, as well as dactylitis, enthesitis, nail disease and quality of life. The safety profile of CZP appears to be similar to that of other TNF-alpha inhibitor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据